Calliditas Therapeutics Ab (Publ) (CALT)

Trade CALT now with
11/18/2021 1:25:29 AM Calliditas Therapeutics Q3 Operating Profit SEK 7.9 Mln Vs. Operating Loss SEK 104.9 Mln Prior Year
8/19/2021 1:27:50 AM Calliditas Therapeutics Q2 Loss/shr SEK 3.20 Vs. Loss/shr SEK 1.50 Prior Year
8/9/2021 3:19:43 AM Calliditas: FDA Grants Fast Track Designation For Setanaxib In Primary Biliary Cholangitis
7/21/2021 3:09:38 AM Calliditas Therapeutics And STADA Partner To Commercialize Specialty Therapy For IgA Nephropathy In Europe
7/15/2021 3:05:08 AM Calliditas Therapeutics Signs Loan Agreement Of Up To The Euro Equivalent Of $75 Mln With Kreos Capital
5/28/2021 9:09:01 AM Calliditas Submits Marketing Authorisation Application For Nefecon To The European Medicines Agency
5/18/2021 1:16:33 AM Calliditas Therapeutics Q1 Loss Per Share SEK 2.51 Vs Loss SEK 1.65 Last Year
4/28/2021 4:36:56 AM Calliditas Therapeutics: FDA Grants Priority Review For Nefecon For IgA Nephropathy; Sets PDUFA Goal Date Of Sept 15
4/23/2021 4:54:51 AM Calliditas Therapeutics: EMA Grants Accelerated Assessment Procedure For Nefecon For IgA Nephropathy
2/4/2021 3:06:58 AM Calliditas Therapeutics Doses First Patient In Phase 3 NefIgArd Open Label Extension Study
1/21/2021 2:47:22 AM Calliditas Therapeutics Says All 360 Patients Enrolled For Global Phase 3 Clinical Trial NefIgArd
1/20/2021 2:16:02 AM Calliditas Announces Clinical Development Plan For Setanaxib
1/18/2021 2:40:48 AM Genkyotex Announces Positive Phase 1 Data In In High-dose Setanaxib Trial